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Results
The baseline characteristics and longitudinal changes were similar when the CB+ group of 172 subjects meeting the strict definition was extended to all 220 subjects presenting with chronic phlegm production. (Table S1 ) Similar results on lung function decline (ml FEV 1 /yr), frequent exacerbations and mortality were observed when the CB+ group was extended to the 220 subjects with chronic phlegm production (β -30.6ml; 95%CI -51.2;-10.08ml ; p=0.004, OR 3.82; 95% CI 2.64-5.53; p<0.001 and HR 1.26; 95%CI 1.01-1.59; p=0.043 respectively). When evaluating the impact of having chronic phlegm production but not meeting the strict definition in these 48 participants, we observed that they did not significantly differ from the CB-control group regarding FEV 1 -decline (ml/yr) and mortality 27.8; p=0.656 and HR 1.04; 95%CI 0.69; 1.58; p=0.845 respectively), but the risk of frequent exacerbations was significantly threefold increased (OR 3.26; 95% CI 1.64-6.47; p=0.001). Since interpretable lung function measurements were missing at baseline in 330 subjects, we evaluated the impact on the different outcomes. The association between chronic bronchitis and the frequent exacerbator phenotype was OR 3.51; 95%CI 2.01-6.10; p<0.001 in COPD subjects without interpretable spirometry at baseline and OR 3.65; 95% CI 2.03-6.56, p<0.001 in COPD subjects with interpretable spirometry at baseline, both adjusted for age, sex and packyears of cigarette smoking. The association between chronic bronchitis and the risk of all-cause death was HR 1.11; 95% CI 0.77-1.61; p=0.581 in COPD subjects without interpretable spirometry at baseline and HR 1.41; 95% CI 1.00-2.00; p=0.053 in COPD subjects with interpretable spirometry at baseline, both adjusted for age, sex and packyears of cigarette smoking. 
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